☰

Sandip Panicker, Ph.D. - Publications

Affiliations: 
University of California, San Diego, La Jolla, CA 
Area:
GIRK channels, addiction, plasticity, G proteins
Tree Info Grants Similar researchers PubMed Report error

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Simmons KT, Chan J, Hussain S, Rose EL, Markham K, Byun TS, Panicker S, Parry GC, Storek M. Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s. Clinical Immunology (Orlando, Fla.). 251: 109629. PMID 37149117 DOI: 10.1016/j.clim.2023.109629  0.342
2019 Freire PC, Muñoz CH, Derhaschnig U, Schoergenhofer C, Firbas C, Parry GC, Panicker S, Gilbert JC, Stingl G, Jilma B, Heil PM. Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal-epidermal junction in bullous pemphigoid. The Journal of Investigative Dermatology. PMID 31229501 DOI: 10.1016/J.Jid.2019.04.025  0.311
2019 Nikitin PA, Rose EL, Byun TS, Parry GC, Panicker S. C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro. Journal of Immunology (Baltimore, Md. : 1950). PMID 30635392 DOI: 10.4049/Jimmunol.1800998  0.369
2018 Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood. PMID 30559259 DOI: 10.1182/Blood-2018-06-856930  0.34
2018 Bartko J, Schoergenhofer C, Schwameis M, Firbas C, Beliveau M, Chang C, Marier JF, Nix D, Gilbert JC, Panicker S, Jilma B. A randomized, first-in-human, healthy volunteer trial of BIVV009, a humanized antibody for the specific inhibition of the classical complement pathway. Clinical Pharmacology and Therapeutics. PMID 29737533 DOI: 10.1002/Cpt.1111  0.368
2018 Nikitin PA, Rose EL, Byun TS, Parry GC, Panicker S. C1s inhibition by BIVV009 prevents complement-enhanced activation of autoimmune human B cells in vitro Molecular Immunology. 102: 193. DOI: 10.1016/J.Molimm.2018.06.166  0.348
2018 Byun T, Singh A, Parry G, Panicker S. Antibody-mediated complement activation is strictly classical pathway driven in human serum but classical and lectin in rat serum Molecular Immunology. 102: 137. DOI: 10.1016/J.Molimm.2018.06.036  0.314
2017 Eskandary F, Jilma B, Mühlbacher J, Wahrmann M, Regele H, Kozakowski N, Firbas C, Panicker S, Parry GC, Gilbert JC, Halloran PF, Böhmig GA. Anti-C1s Monoclonal Antibody BIVV009 in Late Antibody-Mediated Kidney Allograft Rejection - Results from a First-in-Patient Phase 1 Trial. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 28980446 DOI: 10.1111/Ajt.14528  0.38
2017 Mühlbacher J, Jilma B, Wahrmann M, Bartko J, Eskandary F, Schörgenhofer C, Schwameis M, Parry GC, Gilbert JC, Panicker S, Böhmig GA. Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial. Transplantation. 101: 2410-2418. PMID 28926521 DOI: 10.1097/Tp.0000000000001804  0.384
2017 Kasprick A, Holtsche MM, Rose EL, Hussain S, Schmidt E, Petersen F, Panicker S, Ludwig RJ. The anti-C1s antibody TNT003 prevents complement activation in the skin induced by bullous pemphigoid autoantibodies. The Journal of Investigative Dermatology. PMID 28899686 DOI: 10.1016/J.Jid.2017.08.030  0.353
2017 Valenzuela NM, Thomas KA, Mulder A, Parry GC, Panicker S, Reed EF. Complement-Mediated Enhancement of Monocyte Adhesion to Endothelial Cells by HLA Antibodies, and Blockade by a Specific Inhibitor of the Classical Complement Cascade, TNT003. Transplantation. 101: 1559-1572. PMID 28640789 DOI: 10.1097/Tp.0000000000001486  0.353
2017 Wahrmann M, Mühlbacher J, Marinova L, Regele H, Huttary N, Eskandary F, Cohen G, Fischer GF, Parry GC, Gilbert JC, Panicker S, Böhmig GA. Effect of the Anti-C1s Humanized Antibody TNT009 and its Parental Mouse Variant TNT003 on HLA Antibody-induced Complement Activation - A Preclinical in Vitro Study. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 28251805 DOI: 10.1111/Ajt.14256  0.4
2017 Jaeger U, D'Sa S, Schoergenhofer C, Bartko J, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B. Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients Blood. 130: 703-703. DOI: 10.1182/Blood.V130.Suppl_1.703.703  0.331
2016 Colonna L, Parry GC, Panicker S, Elkon K. Uncoupling complement C1s activation from C1q binding in apoptotic cell phagocytosis and immunosuppressive capacity. Clinical Immunology (Orlando, Fla.). PMID 26769276 DOI: 10.1016/J.Clim.2015.12.017  0.377
2016 Panicker S, Drucker C, Hussain S, Parry GC, Gilbert JC, Jilma B, Jaeger U. TNT009 Prevents Erythrocyte C3 Fragment Opsonization and Rescues Reticulocytes from Destruction in Patients with Cold Agglutinin Disease Blood. 128: 94-94. DOI: 10.1182/Blood.V128.22.94.94  0.363
2016 Jilma B, Gilbert JC, Panicker S, Parry GC, Fillitz M, Thomas S, Sillaber C, Bartko J, Jaeger U. Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD) Blood. 128: 2435-2435. DOI: 10.1182/Blood.V128.22.2435.2435  0.308
2016 Panicker S, Parry GC, Fillitz M, Schenk T, Sillaber C, Bartko J, Gilbert JC, Jäger U, Jilma B. TNT009, a monoclonal antibody inhibitor of C1s, induces a rapid and complete remission of anemia in primary cold agglutinin disease patients Immunobiology. 221: 1170-1171. DOI: 10.1016/J.Imbio.2016.06.104  0.376
2015 Peerschke EI, Panicker S, Bussel J. Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor. British Journal of Haematology. PMID 26305671 DOI: 10.1111/Bjh.13648  0.385
2015 Thomas KA, Valenzuela NM, Gjertson D, Mulder A, Fishbein MC, Parry GC, Panicker S, Reed EF. An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 25904443 DOI: 10.1111/Ajt.13273  0.361
2015 Jaeger U, Rose EL, Singh A, Feickert SHA, Panzer S, Jilma B, Gilbert JC, Panicker S. Therapeutic Rationale and Clinical Development of TNT009, an Upstream Classical Pathway Inhibitor, for Cold Agglutinin Disease Blood. 126: 3560-3560. DOI: 10.1182/Blood.V126.23.3560.3560  0.378
2014 Shi J, Rose EL, Singh A, Hussain S, Stagliano NE, Parry GC, Panicker S. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood. 123: 4015-22. PMID 24695853 DOI: 10.1182/Blood-2014-02-556027  0.401
2014 Peerschke EIB, Panicker S, Sughroue AM, Bussel JB. Classical Pathway of Complement Activation in ITP: Inhibition By TNT003, a Novel C1s Inhibitor Blood. 124: 1453-1453. DOI: 10.1182/Blood.V124.21.1453.1453  0.377
2014 Thomas K, Valenzuela N, Parry G, Panicker S, Reed E. TNT003, a Novel Anti-C1s Monoclonal Antibody, Inhibits Anti-HLA Antibody Induced Complement Deposition.: Abstract# A215 Transplantation. 98: 461. DOI: 10.1097/00007890-201407151-01532  0.348
2013 Chen G, Panicker S, Lau KY, Apparsundaram S, Patel VA, Chen SL, Soto R, Jung JKC, Ravindran P, Okuhara D, Bohnert G, Che Q, Rao PE, Allard JD, Badi L, et al. Characterization of a novel CRAC inhibitor that potently blocks human T cell activation and effector functions Molecular Immunology. 54: 355-367. PMID 23357789 DOI: 10.1016/J.Molimm.2012.12.011  0.301
2010 Gever JR, Soto R, Henningsen RA, Martin RS, Hackos DH, Panicker S, Rubas W, Oglesby IB, Dillon MP, Milla ME, Burnstock G, Ford AP. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. British Journal of Pharmacology. 160: 1387-98. PMID 20590629 DOI: 10.1111/J.1476-5381.2010.00796.X  0.33
2004 Panicker S, Cruz H, Arrabit C, Suen KF, Slesinger PA. Minimal structural rearrangement of the cytoplasmic pore during activation of the 5-HT3A receptor. The Journal of Biological Chemistry. 279: 28149-58. PMID 15131114 DOI: 10.1074/Jbc.M403545200  0.551
2002 Panicker S, Cruz H, Arrabit C, Slesinger PA. Evidence for a centrally located gate in the pore of a serotonin-gated ion channel. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 1629-39. PMID 11880493 DOI: 10.1523/Jneurosci.22-05-01629.2002  0.515
Show low-probability matches.